more_reports

The Latest Biotechnology / Pharmaceuticals Articles from Streetwise Reports

Analyst Reveals Undervalued Pharmaceutical Gem in Canada

Research Report
  ()
In a recent research note from Leede Financial Inc. analyst Dr. Douglas Loe said Theratechnologies Inc. (TH:TSX; THTX:NASDAQ) has long term potential.
Tags: Biotechnology / Pharmaceuticals

New Drug for Early AD Shown to be Efficacious, Safe

Research Report
  ()
Trial participants exhibited improvements in cognitive function and activities of daily living, noted a D. Boral Capital report.
Tags: Biotechnology / Pharmaceuticals

Rest of 2025 Rich With Catalysts for Immunotherapy Co.

Research Report
  ()
These anticipated events will advance the oncology firm's lead candidate, for lung-only metastatic osteosarcoma, toward commercialization, noted a D. Boral Capital report.
Tags: Biotechnology / Pharmaceuticals

Four-Year Data on New Drug for Early AD Positive

Research Report
  ()
Long-term treatment with this small molecule seems feasible given its safety and tolerability profile, noted an H.C. Wainwright & Co. report.
Tags: Biotechnology / Pharmaceuticals

Share Price Appreciation of Biotech Due Over Next Six Months

Research Report
  ()
Given its robust pipeline, numerous milestones for this Outperform-rated company are slated to occur in the near-term, noted a Wedbush report.
Tags: Biotechnology / Pharmaceuticals

New Therapy for AATD Could be Best in Class

Research Report
  ()
Updated trial data show it to be safe and efficacious and have a dual mechanism of action, noted an H.C. Wainwright & Co. report.
Tags: Biotechnology / Pharmaceuticals

Biotech Firm Uncovers Gene Therapy Breakthrough in Portugal

  ()
Beam Therapeutics Inc. (BEAM:NASDAQ) shows strong momentum with positive analyst ratings and new data from its BEAM-302 trial in AATD. Find out why experts see major upside potential.
Tags: Biotechnology / Pharmaceuticals

Biotech Co. Has Promising AI-Accelerated Pipeline

Research Report
  ()
Rakovina Therapeutics Inc. (RKV:TSX.V) recently gained analyst coverage from First Berlin Equity Research. Read on to see why this company rates the stock a Buy.
Tags: Biotechnology / Pharmaceuticals

Immunotherapy Company Finds Rare Cancer Breakthrough in U.S.

  ()
OS Therapies Inc. (OSTX:NYSEAMERICAN) announced that its lead drug OST-HER2 was granted Orphan Drug Designation by the FDA for osteosarcoma. Read how the designation could accelerate development and create new investor interest.
Tags: Biotechnology / Pharmaceuticals

Biotech Company Finds High-Impact Alzheimer's Therapy in Europe

  ()
Anavex Life Sciences Corp. (AVXL:NASDAQ) earned positive analyst coverage following new long-term data for blarcamesine in early Alzheimer's disease. Experts pointed to safety, durability, and potential approval pathways. Read more about what they said.
Tags: Biotechnology / Pharmaceuticals

Biopharma Firm Discovers High-Impact CNS Therapy in U.S. With Breakthrough Results

  ()
Reviva Pharmaceuticals Holdings Inc. (RVPH: NASDAQ) is gaining attention with strong Phase 3 results for its lead CNS candidate, brilaroxazine. Here's what analysts are seeing in its long-term potential.
Tags: Biotechnology / Pharmaceuticals

Ascending Dose Trial of FABP5 Inhibitor to Read Out Soon

Research Report
  ()
Meanwhile, a representative from the company advancing the small molecule in the clinic is slated to speak about it at a conference this week, noted a D. Boral Capital report.
Tags: Biotechnology / Pharmaceuticals

New Jersey Pharma Co. Shares Positive Pediatric Study

Research Report
  ()
Aquestive Therapeutics Inc. (AQST:NASDAQ) recently reported that it completed New Drug Application (NDA) submission for Anaphylm and positive pediatric study data for the non-device-based epinephrine product candidate, noted an H.C. Wainwright & Co. research note.
Tags: Biotechnology / Pharmaceuticals

GMP Production of Exosomes Slated for Later This Year

Research Report
  ()
This is a next big step for the biotech in moving its investigational exosome therapy for chronic inflammation into the clinic, noted a D. Boral Capital report.
Tags: Biotechnology / Pharmaceuticals

Biotech Co. Advances AI-Generated Cancer Treatments

  ()
Rakovina Therapeutics Inc. (RKV:TSX.V) receives the first synthesized batch of artificial intelligence-generated ATR inhibitor compounds developed in collaboration with Variational AI. Find out why the technology could revolutionize the way we treat cancer.
Tags: Biotechnology / Pharmaceuticals

Biotech Advances Revolutionary Treatment for Neurodegenerative Diseases

  ()
Clinical-stage biotechnology company Coya Therapeutics Inc.'s (COYA:NASDAQ) regulatory T cell-derived exosome (Treg exosome) program is set to enter Good Manufacturing Production (GMP) late this year, paving the way for an initial clinical study. Find out why one analyst calls the company's work a "potential breakthrough."
Tags: Biotechnology / Pharmaceuticals

Chen Highlights His Premium Silver, Gold Opportunities for Q2

  ()
Even with tariff chaos, asset manager Chen Lin of What is Chen Buying? What is Chen Selling? said he is still bullish in the near term for gold silver. Find out which stocks are his top picks for the coming quarter.
Tags: GoldBiotechnology / PharmaceuticalsSilver

PDUFA Date Nearing for New PSVT Drug

Research Report
  ()
If approved, commercialization will start mid-year; the biopharma behind the treatment offers a potential return of 1,052%, noted an H.C. Wainwright & Co. report.
Tags: Biotechnology / Pharmaceuticals

US$200M Deal Accelerates Phase 3 Gene Therapy for Parkinsons

  ()
MeiraGTx Holdings Plc.'s (MGTX:NASDAQ) partnership with Hologen AI secures US$200 million to advance its Phase 3 gene therapy for Parkinson's. With regulatory milestones ahead, here's what's next.
Tags: Biotechnology / Pharmaceuticals

Biotech Stock Looks Like Is Has a Great Set Up

Contributed Opinion
  ()
Technical Analyst Clive Maund explains why he thinks Hemostemix Inc. (HEM:TSXV; HMTXF:OTCQB; 2VF0:FSE) is an Immediate Strong Buy.
Tags: Biotechnology / Pharmaceuticals

Utah Biotech's Treatment Demonstrates Significant Survival Advantage for ALS Patients

Research Report
  ()
Utah biotech Clene Inc. (CLNN:NASDAQ) recently shared new data, reporting the survival benefit of its CNM-Au8 treatment for ALS patients, according to a D. Boral Capital research note.
Tags: Biotechnology / Pharmaceuticals

Biotech Advancing Pivotal Phase III Breast Cancer Trial

Research Report
  ()
Oncolytics Biotech Inc. (ONCY:NASDAQ; ONC:TSX) recently updated its timelines for the company's clinical testing, regulatory review, and potential commercial launch of its oncolytic reovirus formulation pelareorep in breast cancer, according to a report from Leede Financial Inc.
Tags: Biotechnology / Pharmaceuticals

With Competitor Out, New Drug Gains Edge in Chronic Cough

Research Report
  ()
Phase 2b data, expected in H1/25, could support advancement of the therapeutic into late-stage development, noted a D. Boral Capital report.
Tags: Biotechnology / Pharmaceuticals

New Drug for Major Depressive Disorder Gets Good Surprise

Research Report
  ()
When a key competitor drops out, this treatment moves to top runner position; the biopharma behind it offers 1,084% upside, noted an H.C. Wainwright & Co. report.
Tags: Biotechnology / Pharmaceuticals

Canadian Healthcare Co. Showcases Stable FQ424

Research Report
  ()
Leede Financial Inc. raised its target price on CareRX Corp. (CRRX:TSX; CHHHF:OTCMKTS). Read on to see why one Leede analyst rates the stock as a Buy.
Tags: Biotechnology / PharmaceuticalsHealthcare Services

Showing Results: 1 to 25 of 65 Next